Wilmington Healthcare, a healthcare information group, has named Matthew Kirby as its new business development director, it was reported yesterday.
Kirby will lead a team of business development managers focused on areas such as multichannel marketing and NHS service redesign and he joins from Janssen Pharmaceuticals. He spent seven years at the pharma firm, most recently serving as regional business manager in the UK for its diabetes sales team across the south east. Prior to that his roles included multichannel manager, customer and field support team manager and health economy liaison manager. Before joining Janssen Kirby was at Nycomed Pharmaceuticals, where he served in a market access capacity as a healthcare development specialist.
Gareth Thomas, managing director of Wilmington Healthcare, said, 'We are very pleased to welcome Matthew to his new post, where he will play a pivotal role in supporting and enhancing the work of the business development team. Having spent many years working in the pharma industry in sales, market access and business development roles, Matthew has a wealth of knowledge and experience, and he will be a very valuable asset to the team.'
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes